Sylvia Villeneuve, Judes Poirier, John C. S. Breitner, Jennifer Tremblay-Mercier, Jordana Remz, Jean-Michel Raoult, Yara Yakoub, Jonathan Gallego-Rudolf, Ting Qiu, Alfonso Fajardo Valdez, Bery Mohammediyan, Mohammadali Javanray, Amelie Metz, Safa Sanami, Valentin Ourry, Alfie Wearn, Alexandre Pastor-Bernier, Manon Edde, Julie Gonneaud, Cherie Strikwerda-Brown, Christine L. Tardif, Claudine J. Gauthier, Maxime Descoteaux, Mahsa Dadar, Étienne Vachon-Presseau, Andrée-Ann Baril, Simon Ducharme, Maxime Montembeault, Maiya R. Geddes, Jean-Paul Soucy, Natasha Rajah, Robert Laforce, Christian Bocti, Christos Davatzikos, Lune Bellec, Pedro Rosa-Neto, Sylvain Baillet, Alan C. Evans, D. Louis Collins, M. Mallar Chakravarty, Kaj Blennow, Henrik Zetterberg, R. Nathan Spreng, Alexa Pichet Binette, the PREVENT-AD Research Group
{"title":"The PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond","authors":"Sylvia Villeneuve, Judes Poirier, John C. S. Breitner, Jennifer Tremblay-Mercier, Jordana Remz, Jean-Michel Raoult, Yara Yakoub, Jonathan Gallego-Rudolf, Ting Qiu, Alfonso Fajardo Valdez, Bery Mohammediyan, Mohammadali Javanray, Amelie Metz, Safa Sanami, Valentin Ourry, Alfie Wearn, Alexandre Pastor-Bernier, Manon Edde, Julie Gonneaud, Cherie Strikwerda-Brown, Christine L. Tardif, Claudine J. Gauthier, Maxime Descoteaux, Mahsa Dadar, Étienne Vachon-Presseau, Andrée-Ann Baril, Simon Ducharme, Maxime Montembeault, Maiya R. Geddes, Jean-Paul Soucy, Natasha Rajah, Robert Laforce, Christian Bocti, Christos Davatzikos, Lune Bellec, Pedro Rosa-Neto, Sylvain Baillet, Alan C. Evans, D. Louis Collins, M. Mallar Chakravarty, Kaj Blennow, Henrik Zetterberg, R. Nathan Spreng, Alexa Pichet Binette, the PREVENT-AD Research Group","doi":"10.1002/alz.70653","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment.</li>\n \n <li>All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023.</li>\n \n <li>While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide.</li>\n \n <li>The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 10","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477627/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70653","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection.
Highlights
The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment.
All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023.
While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide.
The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
